What Is This?
Every cell in your body has a built-in self-destruct option. When a cell becomes damaged, stressed, or reaches the end of its useful life, it's supposed to trigger apoptosis — clean, programmed death. But some cells refuse. They stop dividing, stop functioning normally, and instead just sit there, secreting a toxic cocktail of inflammatory signals into surrounding tissue. Scientists call them senescent cells. Everyone else should call them zombie cells.
The problem isn't that senescent cells exist — they actually serve a useful purpose in wound healing and tumour suppression. The problem is accumulation. In youth, the immune system clears them efficiently. With age, clearance slows, and senescent cells pile up. By the time you're in your 60s, they're everywhere — in fat tissue, bone, lungs, brain, kidneys. And they don't just sit quietly. Through a process called the Senescence-Associated Secretory Phenotype (SASP), they continuously signal nearby cells to also become senescent, inflame surrounding tissue, disrupt organ function, and accelerate virtually every hallmark of aging.^1
Senolytics are drugs that selectively destroy these cells while leaving healthy cells intact. The field was effectively born in 2015 when researchers at Mayo Clinic demonstrated that clearing senescent cells in mice extended healthy lifespan by 25–35%, delayed the onset of age-related diseases, and reversed some conditions in already-aged animals. The key compounds being studied in humans today: Dasatinib + Quercetin (D+Q), Fisetin, and Navitoclax.^2
Why Does It Matter?
- It targets the root cause, not the symptoms. Most medicine treats age-related diseases one at a time — a pill for diabetes, a surgery for a blocked artery, another drug for cognitive decline. Senolytics attack the shared upstream cause. Reducing senescent cell burden has shown benefits across cardiovascular disease, diabetes, Alzheimer's, osteoporosis, kidney disease, and pulmonary fibrosis simultaneously, in the same animal.
- The human trial data is now coming in. A 2024 study published in Aging tracked people taking D+Q and Fisetin and measured their biological age via DNA methylation clocks. Results showed measurable reductions in epigenetic age — meaning the drugs appeared to reverse biological aging markers, not just slow them.^3
- One of these is available over the counter today. Fisetin is a polyphenol found in strawberries and sold as a supplement. The Mayo Clinic study found it was the most potent senolytic they tested in mice. Human trials at Mayo are underway. People aren't waiting.
- The dosing protocol is counterintuitive. Unlike most supplements taken daily, senolytics work on an intermittent "burst" schedule — typically 2 days on, then a gap of weeks or months. The idea: kill the senescent cells, let the body clear them, wait for accumulation to rebuild, repeat. Continuous dosing may deplete cells that are temporarily senescent for beneficial reasons.
- This is where longevity is actually going. GLP-1s changed metabolic medicine. Senolytics may do the same for aging itself — not extending lifespan at the cost of healthspan, but extending both simultaneously by removing the cellular garbage that causes decline.
Key People & Players
James Kirkland (Mayo Clinic) — The central figure. His lab did the foundational senolytic mouse studies and is leading most of the serious human trials. He coined the term "senolytic."^4
Jan van Deursen (Mayo Clinic) — Led the 2011 paper that first proved clearing senescent cells in mice delays aging and extends healthspan. The paper that started the field.
Unity Biotechnology — The most funded senolytic biotech. Publicly listed. Has run human trials in osteoarthritis (knee) with mixed results — the joint-injection approach hasn't shown consistent efficacy, but the systemic approach is more promising. Watch their pipeline.^5
Calico (Google/Alphabet) — Alphabet's longevity research lab with essentially unlimited funding. Has senolytics in their portfolio alongside other aging interventions.
David Sinclair (Harvard) — Not a senolytic researcher per se, but his public advocacy for senotherapeutics has massively raised awareness. Has discussed personal use of fisetin.^6
Peter Attia — Covers senolytics in Outlive and his podcast. His take: promising, but not yet ready for clinical recommendation. The most intellectually honest mainstream voice on this.
The Current State
The mouse data is extraordinary. The human data is early but encouraging. The gap between the two is the current frontier.
What we know from mice: Senolytic interventions have extended lifespan by 25–35%, reversed frailty in aged mice, improved cardiovascular function, restored cognitive performance, reduced tumour burden, and rescued pulmonary fibrosis and kidney disease. The effects appear across multiple compounds and multiple labs.
What we know from humans: D+Q in a small trial of patients with diabetic kidney disease showed reduced senescent cell markers in fat tissue, improved physical function, and reduced circulating inflammatory factors — the first proof-of-concept that senolytics work in humans.^7 The 2024 DNA methylation study showed measurable epigenetic age reduction. Multiple larger trials are ongoing.
What's unresolved: Optimal dosing protocol for humans. Long-term safety (killing cells that are senescent for beneficial reasons is a real risk). Whether fisetin, the most accessible option, is potent enough in humans at safe doses. Navitoclax (ABT-263) is highly effective but currently too toxic for routine use.
The practical reality for someone paying attention now:
Fisetin (20mg/kg once monthly or quarterly) is what many self-experimenters are using based on the animal data. At a 70kg bodyweight that's 1,400mg — far above typical supplement doses. It's available, it's generally safe, and the risk-benefit calculation has shifted enough that serious longevity researchers consider it reasonable to start. Dasatinib is a cancer drug requiring a prescription and carries real side effects — not casual territory.
The formal recommendation: watch the Mayo Clinic trials. The informal reality: this is already being used by a significant cohort of biohackers and longevity physicians who aren't waiting for the 10-year RCT.
Best Resources to Learn More
- Mayo Clinic Senolytic Research — The source. Kirkland's lab page with published papers.^8
- Outlive by Peter Attia — Chapter on longevity interventions covers senolytics with appropriate clinical nuance. The best mainstream treatment.^9
- Fisetin as a Senolytic — 2018 EBioMedicine paper — The key mouse study that put fisetin on the map.^10
- 2024 DNA Methylation Study (Aging journal) — First longitudinal human data on D+Q and Fisetin effects on biological age clocks.^3
- Peter Attia's podcast episodes on senolytics — Search "senescent" on peterattiamds podcast. Several deep dives with Kirkland and others.